NICE has produced tools and resources to help you put this guideline into practice. For general help and advice on putting our guidelines into practice, see resources to help you put NICE guidance into practice. Update information November 2021: We withdrew recommendations 1.6.1 to 1.6.4 on valvular surgery and percutaneous intervention because they have been replaced by the NICE guideline on heart valve disease. Minor changes since publication March 2016: MHRA advice on spironolactone and renin-angiotensin system drugs added to recommendation 1.5.4. Accreditation